Transmembrane Glycoprotein Inhibitor

Transmembrane Glycoprotein Inhibitors (22):

Cat. No.	Product Name	Effect	Purity

HY-P99208

Lirilumab	Inhibitor
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.

HY-P990673

Vandortuzumab	Inhibitor	99.00%
Vandortuzumab is a CHO-expressed humanized antibody targeting STEAP1. Vandortuzumab has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 148.74 kDa. The isotype control for Vandortuzumab can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P9983

Lintuzumab	Inhibitor	98.09%
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice.

HY-P99958

Vixtimotamab	Inhibitor
Vixtimotamab (AMV-564; TandAb T564) is a bispecific tetravalent tandem diabody (TandAb) that targets human CD33 and human CD3 antigens. Vixtimotamab can be used for the research of acute myeloid leukemia (AML).

HY-137605

WSF1-IN-1	Inhibitor	99.91%
WSF1-IN-1 (compound 136), an orally active WSF1 inhibitor, can be used in the study for WSF1 (Wolfram syndrome) related tumors, with IC₅₀ values of 0.33 μM and >27 μM in HepG2 parental and HepG2 WFS1 KO cell lines, respectively.

HY-N8102

Echinocystic acid 28-O-β-D-glucoside	Inhibitor	99.11%
Echinocystic acid 28-O-β-D-glucoside is a metabolite of Echinocystic acid by microbial oxidation and glucosidation. Echinocystic acid 28-O-β-D-glucoside is a tissue factor pathway inhibitor, with an IC₅₀ of 10.61 nM.

HY-P99381

XmAb 5592	Inhibitor	99.51%
XmAb 5592 is a humanized, Fc-engineered anti-HM1.24 antibody with enhanced binding to FcγRIIIa and FcγRIIa receptors, augments HM1.24-specific multiple myeloma (MM) cells lysis in vitro via antibody-dependent cellular cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP).

HY-P990607

Indatuximab	Inhibitor	98.04%
Indatuximab is a CHO-expressed, VHH-Fc (huIgG1) type chimeric antibody that targets Syndecan-1/CD138. The predicted molecular weight (MW) of Indatuximab is 146.1 kDa. The isotype control for Indatuximab can refer to Human IgG4 kappa, Isotype Control (HY-P99003).

HY-P9943

Igovomab	Inhibitor
Igovomab is a monoclonal antibody for imaging. Igovomab can be used for ovarian cancer research.

HY-P990061

Polzastobart	Inhibitor
Polzastobart (JTX-8064) is a humanized IgG4 monoclonal antagonist antibody that selectively binds LILRB2 and prevents it from binding its ligands, classical and non-classical MHC I molecules. Polzastobart enhances pro-inflammatory cytokine production in macrophages by blocking the ability of LILRB2 to bind HLA-A/B and/or HLA-G, a marker of immunotolerance on cancer cells. Polzastobart is a macrophage immune checkpoint inhibitor.

HY-P990267

Anti-Mouse CD45RB Antibody (MB23G2)	Inhibitor
Anti-Mouse CD45RB Antibody (MB23G2) is a rat-derived IgG2a, κ type antibody inhibitor, targeting to mouse CD45RB.

HY-P990030

Ralzapastotug	Inhibitor
Ralzapastotug (AB-308) is an anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) IgG1 monoclonal antibody. Ralzapastotug is a monoclonal antibody targeting amino acids 106-126 of the cellular prion protein PrP^C.

HY-P990357

Anti-CD69 Antibody	Inhibitor
Anti-CD69 Antibody is a human-derived antibody expressed in CHO, targeting CD69. The predicted molecular weight (MW) of Anti-CD69 Antibody is 150 kDa. The isotype control for Anti-CD69 Antibody can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990422

Anti-GPC1/Glypican-1 Antibody	Inhibitor
Anti-GPC1/Glypican-1 Antibody is a CHO-expressed human monoclonal antibody that targets GPC1/Glypican-1. The Anti-GPC1/Glypican-1 Antibody is composed of a muIgG1 heavy chain and a mκ light chain, with a predicted molecular weight (MW) of 150 kDa. For isotype control of the Anti-GPC1/Glypican-1 Antibody, please refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990746

Lancastotug	Inhibitor
Lancastotug is an anti-TIGIT human IgG1 κ monoclonal antibody. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P10551

Apo A-I mimetic 5A peptide	Inhibitor
Apo A-I mimetic 5A peptide is a synthetic peptide molecule designed based on the structure and function of naturally occurring apolipoprotein A-I (Apo A-I). Apo A-I mimetic 5A peptide can promote the efflux of cholesterol from cells and help reduce the accumulation of cholesterol in cells. Apo A-I mimetic 5A peptide also shows anti-inflammatory activity and can reduce inflammatory markers in blood and tissues. Apo A-I mimetic 5A peptide can be used in the study of cardiovascular diseases.

HY-P990751

Nelmastobart	Inhibitor
Nelmastobart is an anti-BTN1A1 human IgG4 κ monoclonal antibody. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).

HY-165245

SBI-183	Inhibitor
SBI-183 is an orally active inhibitor of QSOX1 (K_d: 20 μM). SBI-183 suppresses the proliferative and invasive phenotype of renal cancer cell lines, including triple negative breast cancer cell line, lung adenocarcinoma cell line and pancreatic ductal adenocarcinoma. SBI-183 inhibits tumor growth in two human xenograft mouse models of renal cell carcinoma in vivo .

HY-P990353

Anti-CD4 Antibody (TRX1)	Inhibitor
Anti-CD4 Antibody (TRX1) is a humanized antibody expressed in CHO cells that targets CD4. Anti-CD4 Antibody (TRX1) has a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-CD4 Antibody (TRX1) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990467

Anti-MICB Antibody	Inhibitor
The Anti-MICB Antibody is a humanized antibody expressed in CHO cells, targeting MICB. The Anti-MICB Antibody contains a huIgG2 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 143.66 kDa. The isotype control for the Anti-MICB Antibody can be referenced as Human IgG2 kappa, Isotype Control (HY-P99002).

Name
Email *

	Sorry, but the email address you supplied was invalid.